Chinese life-science reagent supplier making recombinant proteins and antibodies for biopharma R&D, diagnostics and vaccine development.
Chinese life-science reagent supplier making recombinant proteins and antibodies for biopharma R&D, diagnostics and vaccine development.
Sells research-grade proteins and antibodies from a catalogue in small lots to labs, and also does contract research and manufacturing work for drug developers. Product sales carry the company, and a large share goes to customers abroad. Demand rose sharply with vaccine and diagnostic research during COVID.
In one line: A Chinese Bio-Techne/R&D Systems.
Moat: narrow (scale, process know-how, installed base). Broad, validated catalog of research-grade proteins used across many biopharma R&D pipelines.
Headquarters: Beijing, China · Founded: 2009 · Employees: 1,069
Size Sino Biological (301047.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.60B, the 1426th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥87.67 on 18 Nov 2026.
Performance Over six months the shares gained 26.9%, against -9.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 20.0% over the last twelve months (peer median +6.6%); the operating margin is 16.8% (peer median 12.0%).
Valuation It trades at 51.6× forward earnings against a peer median of 23.8× (2nd most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is -15%, so the hurdle is +46 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.1 points below its cost of capital (11.0% WACC).
Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥792M | CN¥694M | CN¥614M | CN¥646M | CN¥568M |
| Revenue growth | — | +13% | -5% | +14% | — |
| Gross profit | CN¥618M | CN¥448M | CN¥389M | CN¥481M | CN¥455M |
| EBITDA | n/a | CN¥191M | CN¥130M | CN¥213M | CN¥247M |
| Net income | CN¥179M | CN¥148M | CN¥122M | CN¥260M | CN¥303M |
| Free cash flow | CN¥120M | CN¥122M | CN¥130M | -CN¥645M | CN¥205M |
| Capital expenditure | CN¥159M | CN¥101M | CN¥69.9M | CN¥1.04B | CN¥156M |
| Total debt | CN¥41.1M | CN¥53.5M | CN¥67.4M | CN¥85.1M | CN¥70.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sino Biological 301047.SZ | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% |
| Acrobiosystems 301080.SZ | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% |
| Bio-Techne TECH | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301047.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.3% | -3.8% | 2nd lowest of 21 |
| 6-month return | +26.9% | -9.1% | 2nd highest of 20 |
| Distance from 52-week high | -46.9% | -29.4% | 4th lowest of 21 |
| Revenue growth (TTM) | +20.0% | +6.6% | 5th highest of 20 |
| Operating margin | 16.8% | 12.0% | 5th highest of 20 |
| Forward P/E | 51.6× | 23.8× | 2nd most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 31.1% | 6.0% | 4th most demanding of 16 |
| Growth delivered (Del g) | -15.1% | +6.8% | lowest of 16 |
| Hurdle (Req g minus delivered) | +46.2 pp | +2.0 pp | most demanding of 16 |
| ROIC minus cost of capital | -4.1 pp | +1.2 pp | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |